Phase 2
NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.
MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)
Bone marrow transplants are both incredibly risky as well as expensive procedures. Nonetheless, they are still effective and have been used by doctors since the 1950s, with many successful procedures completed over the years.
The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials
Perhaps the last big hope for a successful Alzheimer’s drug just died. Biogen and its collaboration partner, Eisai, announced they were discontinuing the global Phase III clinical trials of aducanumab in patients with mild cognitive impairment from Alzheimer’s.
PRESS RELEASES